

Original Research Article

***Helicobacter pylori* infection among symptomatic adults in a tertiary hospital in Southwestern Nigeria: A retrospective study"**

ABSTRACT

Aim: To determine the prevalence of *Helicobacter pylori* (*H. pylori*) infection among symptomatic adults in a tertiary hospital in a peri-urban setting in Southwestern Nigeria.

Methodology: It was a retrospective, cross-sectional study conducted in the Medical Microbiology Laboratory, Department of Medical Microbiology and Parasitology, Babcock University Teaching Hospital, Ilisan-Remo, Ogun State, Nigeria, between January 2022 and June 2024. The study involved a review of the medical microbiology laboratory records to evaluate the *H. pylori* stool antigen results of samples obtained from adults with gastrointestinal symptoms suggestive of *H. pylori* infection.

Results: A total of 1061 adults were included in the study with females accounting for 56.2% of the participants. The age range of the participants was 18 – 95 years with a mean age of 34.59 ± 15.51 . The prevalence rate of *H. pylori* infection was 32.4% (344/1061). Females accounted for 50.6% of *H. pylori*-positive participants in the study population. The infection was higher in females (50.6%) than in males (49.4%) and it was statistically significant ($P = 0.011$). However, a higher proportion (36.6%) of males had the infection than females (29.2%). The age group 21 – 30 years accounted for 23.3% of the *H. pylori*-positive participants while 37.6% of participants in the age group 41 -50 years were *H. pylori*-positive, however it was not statistically significant.

Conclusion: *H. pylori* infection is prevalent among symptomatic adults in this locality. Hence, screening for *H. pylori* is recommended for detection, prompt treatment and eradication of *H. pylori* infection to prevent long-term complications.

Keywords: *Helicobacter pylori*, Prevalence, Stool antigen test, Adults, Southwest Nigeria

1. INTRODUCTION

Helicobacter pylori (*H. pylori*) is a spiral Gram-negative bacterium which selectively colonizes the gastric epithelium in humans [1]. It is the most prevalent bacteria resulting in chronic bacterial infection worldwide [2,3]. It infects more than half of the world's population [4]. A meta-analysis reported a global prevalence rate of 44.3% with the prevalence varying between and within countries, within a single city, and also subgroups within a population [5,6]. The prevalence was higher in developing countries, 50.8% and lower in developed countries, 34.7% [7,8]. A prevalence rate as high as 87.8% was reported in Northern Nigeria [9] while 51.4% and 34.2% were reported in Southern Nigeria [10,11]. In Africa, prevalence rates of 70.41%, 88%, 75%, 70.8% and 66.1% have been reported in Togo, Ghana, Rwanda, Burundi, and Egypt respectively [5]. Lower prevalence rates have been reported in Germany (20%), North America (23.1%), Australia (24.6%) and Asia (48.8%) [5]. The prevalence rate is influenced by age, gender, host genetic makeup, the immune response of the host, pathogenicity of the *H. pylori* strain, urbanization, access to health facilities and portable water, socioeconomic status, level of urbanization, sanitation conditions among others [3,9–11].

The infection is usually acquired in childhood with the probable mode of transmission being oral-oral or faecal-oral route [5,10]. *H. pylori* infection is asymptomatic in most individuals and when symptomatic, the symptoms are non-specific [6]. However, common symptoms experienced include dyspepsia, heartburn, nausea, emesis, constipation or diarrhoea [15,16]. Chronic *H. pylori* infection has been implicated in several gastrointestinal disorders. It is involved in the pathogenesis of chronic gastritis, peptic ulcer disease, gastric cancer, and gastric mucosal-associated lymphoid tissue lymphoma (MALT) [1,5]. Furthermore, *H. pylori* has been categorized by the World Health Organization (WHO) as a group-I carcinogen due to the report of it being the greatest single risk factor for the development of gastric cancer [17]. In addition, *H. pylori* has been implicated in the aetiology of colorectal cancer, myocardial infarction and liver cirrhosis [13,14]. It is recommended that individuals with symptoms suggestive of peptic ulcer disease should be tested and treated to prevent the long-term sequelae

[2,6]. Therefore, it is essential to accurately detect the organism to enhance effective treatment and prevention of its long-term sequelae.

The modalities in diagnosing *H. pylori* infection can be invasive and non-invasive with each having its merits and demerits. The invasive tests require obtaining biopsies through an endoscope for histology, culture, rapid urease test, polymerase chain reaction, and fluorescence in-situ hybridization [5, 18, 19]. The non-invasive diagnostic modalities include stool antigen test, ¹³C urea breath test, serology, salivary, urinary or blood antibody tests, and stool PCR [1, 5, 18]. Non-invasive tests are crucial in primary care as they are more convenient, faster and cheaper with better patient compliance. The HpSA test is simple and effective at detecting ongoing infection as it identifies the antigen of the bacterium [3].

There is a paucity of data on the burden of *H. pylori* infection in our locality. Hence, this study sought to determine the prevalence of *H. pylori* infection among symptomatic adult patients in Babcock University Teaching Hospital, Ilishan-remo, Southwestern Nigeria. This will provide insight into the burden of the disease and may facilitate improved clinical practice and decisions regarding the management of the infection.

2. MATERIAL AND METHODS

2.1 Study site

The study was conducted in the Department of Medical Microbiology, Babcock University Teaching Hospital, Ilishan-Remo, Ogun State, Southwestern Nigeria. The hospital is a 240-bed tertiary hospital located in a peri-urban setting of Ogun state. The hospital serves as a referral centre for primary and secondary health facilities in the state and the neighbouring states in Southwestern Nigeria. It provides general outpatient services, specialist clinics, antenatal care, radiological, pharmaceutical and laboratory services. Patients suspected of having *H. pylori* infection are usually referred by clinicians to the laboratory for laboratory diagnosis.

2.2 Study design

Data from symptomatic adults (persons ≥ 18 years) referred to the medical microbiology laboratory for *H. pylori* stool antigen (HpSA) test between January 2022 and June 2024 were retrospectively analysed.

2.3 Inclusion criteria

The inclusion criteria included all patients older than 17 who had undergone the *H. pylori* stool antigen test between January 2022 and June 2024.

2.4 Sample size and sampling method

The laboratory records were carefully reviewed to identify all patients that met the inclusion criteria. A total of 1,061 fulfilled the criteria and were included in the study.

2.5 Ethical considerations

Ethical approval for the study was obtained from the Babcock University Health Research and Ethics Committee (BUHREC No 693/22). Written informed consent was not required due to the retrospective nature of the study. However, the confidentiality and anonymity of patients' data were ensured in accordance with the Declaration of Helsinki.

2.6 Laboratory procedure

Fresh stool samples sent to the Medical Microbiology Laboratory for HpSA test are routinely collected in plain universal bottles and tested using a rapid strip *H. pylori* stool antigen kit (Lotus NL B.V, The Hague, Netherlands) as per the manufacturer's instruction. This is a rapid, qualitative, sandwich, solid-phase immunochromatographic assay based on the lateral flow chromatography technique and detects *H. pylori* antigen in human stool. The kit's sensitivity and specificity were 99.0%, and 97.9% respectively and the positive and negative predictive values were 99.0% and 97.9% respectively.

2.7 Data collection and analysis

Data was collected using a checklist designed for this study. Data collected included age, gender, symptoms and results of the HpSA test. Data was analysed using IBM_SPSS Statistics for Windows software version 21 (IBM, Armonk, New York, USA). Descriptive statistics such as proportions, means, standard deviation, and cross-tabulations were used to characterize the study participants. Chi-square test was used to determine the associations between demographic

characteristics and the prevalence of *H. pylori* infection. A *P*-value (*P*) of < .05 with a 95% confidence interval was considered statistically significant.

3. RESULTS

A total of 1,061 patients were included in the study with 465 (43.8%) males and 596 (56.2%) females giving a male-to-female ratio of 1:1.3. Their ages ranged between 18 – 95 years with a mean age of 34.59 ± 15.51 . The mean age for females was 33.5 ± 16.44 years while that of males was 35.9 ± 14.15 years. The age group ≤ 20 were the highest proportion of the participants (272, 25.6%) next was the age group 21 – 30 years (238, 22.4%), while those ≥ 60 years made up the least proportion (79, 7.4%) (Table 1). The symptoms reported among the participants were dyspepsia, epigastric pain, chest pain, and abdominal pain.

Table 1: Characteristics of the participants

Variables		Frequency	Percentage
Gender	Female	596	56.2
	Male	465	43.8
Age group (years)	≤ 20	272	25.6
	21 -30	238	22.4
	31 – 40	214	20.2
	41 – 50	178	16.8
	51 - 60	80	7.5
	≥ 60	79	7.4
	Total	1,061	100.0

Prevalence of *H. pylori* infection

The prevalence of *H. pylori* infection among the participants was 32.4% (344/1061). The prevalence was slightly higher in females (16.4%) compared to males (16.0%) and it was statistically significant ($P = .01$) (Table 2). The prevalence rates varied among the age groups with the age group 21 – 30 having the highest prevalence (7.5%) while the age group > 61 had the lowest prevalence (2.4%). However, this finding was not statistically significant ($P = .43$).

Table 2: Distribution of *H. pylori* infection with the characteristics of the participants

Variables		<i>H. pylori</i> - positive (N=344) n (%)	<i>H. pylori</i> - negative (%) (N=717) n (%)	Total (N=1,061) n (%)	χ^2	p-value

Gender	Female	174 (16.4)	422 (39.8)	596 (56.2)	6.466	0.011
	Male	170 (16.0)	295 (27.8)	465 (43.8)		
Age (years)	≤ 20	76 (7.2)	196 (18.5)	272 (25.6)	4.889	0.430
	21 – 30	80 (7.5)	158 (14.9)	238 (22.4)		
	31 – 40	70 (6.6)	144 (13.6)	214 (20.2)		
	41 – 50	67 (6.3)	111 (10.5)	178 (16.8)		
	51 – 60	26 (2.5)	54 (5.1)	80 (7.5)		
	≥ 61	25 (2.4)	54 (5.1)	79 (7.4)		
	Total	344 (32.4)	717 (67.6)	1,061 (100.0)		

Further analysis of *H. pylori* infection among the age groups shows that about a third of participants in almost all the age groups tested positive for *H. pylori* (Table 3) with about 40% of the age group 41 - 50 having *H. pylori* infection. The age group 21- 30 accounted for about a quarter of the participants that tested positive for *H. pylori* while the age groups ≤ 20, 31 - 40, and 41 – 50 years each accounted for about a fifth of *H. pylori*-positive participants.

Table 3: Prevalence of *H. pylori* infection within and across the age groups of the participants

Age (years)	<i>H. pylori</i> - positive (N= 344), (Row%, Column %)	<i>H. pylori</i> -negative (%) (N=717), (Row%, Column %)	Total (N=1061), (Row%, Column %)	X ²	p-value
≤ 20	76 (27.9, 22.1)	196 (72.1, 27.3)	272 (100, 25.6)	4.889	0.430
21 – 30	80 (33.6, 23.3)	158 (66.4, 22.0)	238 (100, 22.4)		

31 – 40	70 (32.7, 20.3)	144 (67.3, 20.1)	214 (100, 20.2)		
41 – 50	67 (37.6, 19.5)	111 (62.4, 15.5)	178 (100, 16.8)		
51 – 60	26 (32.5, 7.6)	54 (67.5, 7.5)	80 (100, 7.5)		
≥ 61	25 (31.6, 7.3)	54 (68.4, 7.5)	79 (100, 7.4)		

Females contributed a larger proportion of the number of *H. pylori*-positive participants (50.6%) compared to males (49.4%) (Figure 1). However, a larger proportion of males tested positive for *H. pylori* (36.6%) compared to females (29.2%) (Table 4).




Figure 1: Prevalence of *H. pylori* infection by gender

Table 4: Prevalence of *H. pylori* infection within and across the gender of the participants

Gender	<i>H. pylori</i> -positive (N=)	<i>H. pylori</i> -negative (%)	Total (N=1061),	X^2	p-value

	344), (Row%, Column %)	(N=717), (Row%, Column %)	(Row%, Column %)		
Female	174 (29.2, 50.6)	422 (70.8, 58.9)	596 (100, 56.2)	6.466	0.011
Male	170 (36.6, 49.4)	295 (63.4, 41.1)	465 (100, 43.8)		
Total	344 (34.2, 100)	717 (67.6, 100)	1061 (100.0, 100)		

4. DISCUSSION

This study documents the prevalence of *H. pylori* infection among symptomatic adults in a peri-urban setting in Southwestern Nigeria with a prevalence of 34.2%. The prevalence rate observed in this study is high and suggests that *H. pylori* infection is significant among adults in the locality. This finding is similar to the high prevalence rates reported in Nigeria and other developing countries. However, Ophori *et al.* and Omosor *et al.* in Delta State reported relatively higher prevalence rates of 89.7% and 52.5% respectively among asymptomatic adults in Delta State, Nigeria [1,20]. Nwachukwu *et al.* also reported a high prevalence of 52% in Nnewi, Southeast, Nigeria [21]. The relatively lower prevalence rate observed in this study may be attributable to the diagnostic modality employed as the HpSA test detects only current infections. In contrast, Ophori *et al.*, Omosor *et al.* and Nwachukwu *et al.* employed a serological test which detects *H. pylori* antibody (Immunoglobulin G) and does not differentiate current from past *H. pylori* infections [22]. Jemilohun *et al.* reported a prevalence of 64% among symptomatic patients in Ibadan, Nigeria [23], Zawayia *et al.* reported 65% in North Central Nigeria [24] and Aboderin *et al.* reported 73% in Ile-Ife [25] all in Nigeria. A study by Smith *et al.* reported a prevalence rate of 37.5% among symptomatic adults in 6 tertiary hospitals in Nigeria [26]. However, a study among university students in Karu, North-central Nigeria reported a very low prevalence of 5.5% [27]. Other African countries have reported prevalence rates of 70.41% in Togo, 88% in Ghana, 75% in Rwanda, 70.8% in Burundi, and 66.1% in Egypt [5]. A study in Saudi Arabia reported a prevalence rate of 55% among symptomatic adults [28]. Meanwhile, lower prevalence rates have been reported in Germany (20%), North America (23.1%) and Australia (24.6%) [5]. These variations in the prevalence rates of these studies agree with the reports that prevalence rates differ within and between countries, within a city and subgroups of a populace as well as developing countries having higher prevalence rates than developed countries [5–7,22]. Factors attributed to the variation in the prevalence include socioeconomic status, sanitation, hygiene and water supply [3,9–11]. Furthermore, there have been reports of reduction in the prevalence rates of *H. pylori* infection in cities, countries and globally, and this has been attributed to improvement in the standard of living, and living conditions [29].

In this study, the prevalence was higher among males (36.6%) than females (29.2%) and statistically significant. This is similar to reports from other studies whereby males had a higher prevalence of *H. pylori* infection than females [1,30]. Some other studies reported a higher prevalence among females than males [10–12,24,27,31]. The higher prevalence in females is attributed to high social activities among women [11].

The age group 41–50 years had the highest (37.6%) prevalence of *H. pylori* infection while the lowest was in the age group ≤ 20 years. There are reports of an increasing prevalence of *H. pylori* with age with a peak at about 30 years and subsequent spontaneous elimination of the infection in the latter years possibly due to changes in the standard of living or as an indirect benefit from the use of antibiotics for another purpose [27,29–31].

5. LIMITATIONS

This was a retrospective study hence we were unable to access the clinical records of the participants to determine cessation of the use of antibiotics for 4 weeks, H2 receptor blockers, proton pump inhibitors, N-acetylcysteine, bismuth preparations for 2 weeks, and antacids for 2 days before the test and exclude them from the study.

6. CONCLUSION

This study reports a high (32.4%) prevalence of *H. pylori* infection among symptomatic patients in a peri-urban setting in Southwestern Nigeria with a higher proportion of males having the infection than females. Therefore, *H. pylori* screening is recommended for detection, prompt treatment and eradication of *H. pylori* infection to prevent its associated sequelae.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

The authors declare that no generative AI technologies such as Large Language Models (Gemini, ChatGPT etc.) and text to image generators have been used during writing or editing of the manuscript.

CONSENT:

Due to the retrospective nature of the study, informed consent was not deemed necessary.

ETHICAL APPROVAL

Ethical approval for the study was obtained from Babcock University Health Research and Ethics Committee

REFERENCES

1. Omosor KI, Omosor OH, Ibeh IN, Adejumo BIG, Abdulkadir UI, Dimkpa U, et al. Seroprevalence of Helicobacter pylori infection and risk factors among asymptomatic subjects in Delta State, Nigeria. *Adv. Microbiol.* 2017;7:641–52. <https://doi.org/10.4236/aim.2017.79050>
2. Nithiyananthan CM, Senthil KK, Dinesh K, Alagappan. Prevalence of Helicobacter pylori infection in patients with dyspepsia undergoing upper GI endoscopy in a rural tertiary care centre. *Afr. J. Biol. Sci.* 2024;6:915–28. <https://doi.org/10.48047/AFJBS.6.12.2024.915-928>
3. Muhina IAI, Sadiq AM, Said FH, Raza FM, Gharib SK, Muhali SS, et al. Feco-prevalence, endoscopic pattern and associated factors of Helicobacter pylori infection among symptomatic adult patients in Northern Tanzania. *PLOS ONE* 2024;19:e0307705. <https://doi.org/10.1371/journal.pone.0307705>
4. Kooffreh-Ada M., Okonkwo U, Ugbong E, Essien A, Chukwudike E, Edogiawerie D, et al. Prevalence of Helicobacter pylori infection among dyspepsia patients in Calabar. *Glob. J. Pure Appl. Sci.* 2019;25:145–51. <https://dx.doi.org/10.4314/gjpas.v25i2.3>
5. Smith S Ifeanyi, Ajayi A, Jolaiya T, Onyekwere C, Setshedi M, Schulz C, et al. Helicobacter pylori infection in Africa: Update of the current situation and challenges. *Dig. Dis.* 2022;40:535–44. <https://doi.org/10.1159/000518959>
6. Costa LCMC, Das Graças Carvalho M, La Guárdia Custódio Pereira AC, Teixeira Neto RG, Andrade Figueiredo LC, Barros-Pinheiro M. Diagnostic methods for *Helicobacter pylori*. *Med. Princ. Pract.* 2024;33:173–84. <https://doi.org/10.1159/000538349>
7. Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. *Aliment. Pharmacol. Ther.* 2018;47:868–76. <https://doi.org/10.1111/apt.14561>
8. Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity. *Toxins* 2019;11:677. <https://doi.org/10.3390/toxins11110677>
9. Bello AK, Umar AB, Borodo MM. Prevalence and risk factors for Helicobacter pylori infection in gastroduodenal diseases in Kano, Nigeria. *Afr. J. Med. Health Sci.* 2018;17:41–6. <https://doi.org/10.5897/AJMHS.9000010>
10. Odigie AO, Adewole AJ, Ekunwe AA. Prevalence and factors associated with Helicobacter pylori infection among treatment naïve dyspeptic adults in University of Benin Teaching Hospital, Benin City, Nigeria. *Afr. J. Clin. Exp. Microbiol.* 2020;21:97–105. <https://doi.org/10.4314/ajcem.v21i2.3>
11. Chukwuma OM, Chukwuma G, Manafa P, Ibeh N, Jeremiah Z. Prevalence and possible risk factors for Helicobacter pylori seropositivity among peptic ulcerative individuals in Nnewi Nigeria. *J. Curr. Biomed. Res.* 2017;1:39–45.
12. Smith SI, Ajayi A, Jolaiya TF, Essiet U. Prevalence, diagnosis and treatment of Helicobacter pylori infection in Nigeria. *Niger. J. Gastroenterol. Hepatol.* 2022;14:2. https://doi.org/10.4103/njgh.njgh_10_22
13. Talaiezhadeh A, Borhani M, Moosavian M, Rafiei A, Neisi AK, Hajiani E, et al. Prevalence of Helicobacter pylori infection evaluated by stool antigen test in Khuzestan Province since September to October 2009, south-west of Iran: A population based study. *Jundishapur J. Microbiol.* 2013;6:100–4. <https://doi.org/10.5812/jjm.4545>
14. Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. *Braz. J. Microbiol.* 2022;53:33–50. <https://doi.org/10.1007/s42770-021-00675-0>

15. Emerenini F C, Nwolisa E C, Iregbu F U, Eke C B, Ikefuna A N. Prevalence and risk factors for *Helicobacter pylori* infection among children in Owerri, Nigeria. *Niger. J. Clin. Pract.* 2021;24:1188–93. https://doi.org/10.4103/njcp.njcp_687_20
16. Helmbold L, Ghebremedhin B, Bellm A, Hopkins MA, Wirth S, Aydin M. Increased antibiotic resistance in children with *Helicobacter pylori* infection: A retrospective study. *Pathogens* 2022;11:178. <https://doi.org/10.3390/pathogens11020178>
17. Ahn HJ, Lee DS. *Helicobacter pylori* in gastric carcinogenesis. *World J. Gastrointest. Oncol.* 2015;7:455–65. <https://doi.org/10.4251/wjgo.v7.i12.455>.
18. Oluwasola A, Okolo C, Otegbayo J, Adeniyi B, Kehinde A, Akere A, et al. Comparative study of methods of diagnosis of *Helicobacter pylori* infection in Ibadan. *Niger. J. Gastroenterology Hepatol.* 2011;Vol. 3:31–8.
19. Bashir SK, Khan MB. Overview of *Helicobacter pylori* infection, prevalence, risk factors, and its prevention. *Adv. Gut Microbiome Res.* 2023;2023:9747027. <https://doi.org/10.1155/2023/9747027>
20. Ophori EA, Isibor C, Onemu SO, Johnny EJ. Immunological response to *Helicobacter pylori* among healthy volunteers in Agbor, Nigeria. *Asian Pac. J. Trop. Med.* 2011;1:38–40. [https://doi.org/10.1016/S2222-1808\(11\)60009-1](https://doi.org/10.1016/S2222-1808(11)60009-1)
21. Nwachukwu EP, Onwurah OW, Amilo GI, Onwuasoanya UF, Ezeugwunne IP. Prevalence of *Helicobacter pylori* among patients with gastritis attending Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria. *Ann. Curr. Gastroenterol. Rep.* 2020;1:1–4.
22. Ansari S, Yamaoka Y. *Helicobacter pylori* infection, its laboratory diagnosis, and antimicrobial resistance: A perspective of clinical relevance. *Clin. Microbiol. Rev.* 2022;35:e00258-21. <https://doi.org/10.1128/cmr.00258-21>.
23. Jemilohun AC, Otegbayo JA, Ola SO, Oluwasola OA, Akere A. Prevalence of *Helicobacter pylori* among Nigerian patients with dyspepsia in Ibadan *Pan Afr. Med. J.* 2010;6. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3120989/>
24. Zawaya K P, Dunga J A, Adamu Y, Bathnna SJ, Liman Haruna U., Musa Jafiada J., et al. *Helicobacter pylori* infection a risk for upper gastrointestinal diseases among patients in North Central Nigeria. *Niger. J. Med.* 2021;30:607–14. https://doi.org/10.4103/NJM.NJM_45_21
25. Aboderin OA, Abdu AR, Odetoyin B 'Wumi, Okeke IN, Lawal OO, Ndububa DA, et al. Antibiotic resistance of *Helicobacter pylori* from patients in Ile-Ife, South-west, Nigeria. *Afr. Health Sci.* 2007;7:143–7.
26. Smith S, Jolaiya T, Fowora M, Palamides P, Ngoka F, Bamidele M, et al. Clinical and socio-demographic risk factors for acquisition of *Helicobacter pylori* infection in Nigeria. *Asian Pac. J. Cancer Prev. APJCP* 2018;19:1851–7. <https://doi.org/10.22034/APJCP.2018.19.7.1851>
27. Abioye JOK, Anarado KS, Babatunde S. Seroprevalence of *Helicobacter pylori* infection among Students of Bingham University, Karu in North-Central Nigeria. *Int. J. Pathog. Res.* 2021;38–47. <https://doi.org/10.9734/ijpr/2021/v7i430190>
28. Ahmed YH, Mohammed RA, Alghamdi IK, Alqahtani MF, Alhelali SN, Sultan I, et al. Histopathological findings in adult patients with dyspepsia and their association with *Helicobacter pylori* infection. *Cureus* 15:e50981. <https://doi.org/10.7759/cureus.50981>
29. Malaty HM. Epidemiology of *Helicobacter pylori* infection. *Best Pract. Res. Clin. Gastroenterol.* 2007;21:205–14. <https://doi.org/10.1016/j.bpg.2006.10.005>
30. Saidu AY, Munir G, Salihu Y, Sani NM, Muhammad Y, Dodo AM. Seroprevalence of *Helicobacter pylori* among adult in Sokoto Metropolis. *J. Nurs. Health Sci.* 2015;4:64–9. <https://doi.org/10.9790/1959-04516469>
31. Ishaleku D, Ihiabe HA. Seroprevalence of *Helicobacter pylori* infection among students of a Nigerian University. *Asian Pac. J. Trop. Med.* 2010;3:584–5. [https://doi.org/10.1016/S1995-7645\(10\)60142-3](https://doi.org/10.1016/S1995-7645(10)60142-3)